` 083790 (CrystalGenomics Inc) vs KOSPI 200 Comparison - Alpha Spread

C
083790
vs
K
KOSPI 200

Over the past 12 months, CrystalGenomics Inc has underperformed KOSPI 200, delivering a return of -43% compared to the KOSPI 200's +83% growth.

Stocks Performance
083790 vs KOSPI 200

Loading
083790
KOSPI 200
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
083790 vs KOSPI 200

Loading
083790
KOSPI 200
Difference
www.alphaspread.com

Performance By Year
083790 vs KOSPI 200

Loading
083790
KOSPI 200
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
CrystalGenomics Inc vs Peers

KOSPI 200
083790
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

CrystalGenomics Inc
Glance View

Market Cap
107.1B KRW
Industry
Biotechnology

CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2006-01-06. The firm operates its business through four segments. The Drug Substance Manufacturing segment manufactures and sells drug substances such as anti-inflammatory analgesics, antispasmodics, and asthma treatments. The Finished Drug Manufacturing segment produces and supplies finished drugs such as cephalosporin antibiotics. The Pharmaceutical Research and Development segment is engaged in the provision of clinical trial analysis and technical services, and sales of new drugs. The company also engages in real estate rental business. The Other segment is engaged in the manufacture and sale of hot pats and other household goods.

Intrinsic Value
1 182.06 KRW
Overvaluation 15%
Intrinsic Value
Price
C
Back to Top